TP53 and ovarian cancer: To confirm this observation, we evaluated the survival probability in the cohort of the HSP90-highly expressed, TP53-mutated ovarian cancer patients, because HSP90 was shown to considerably dampen MDM2-E3 activity in cancer34,35.